Back to Journals » Journal of Blood Medicine » Volume 4
New developments in the management of congenital Factor XIII deficiency
Authors Fadoo Z, Merchant Q, Rehman KA
Received 28 February 2013
Accepted for publication 18 April 2013
Published 28 May 2013 Volume 2013:4 Pages 65—73
DOI https://doi.org/10.2147/JBM.S32693
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Zehra Fadoo,1 Quratulain Merchant,2,* Karim Abdur Rehman2,*
1Department of Pediatrics and Child Health, 2Medical College, Aga Khan University, Karachi, Pakistan
*These authors contributed equally to this work
Abstract: Congenital Factor XIII (FXIII) deficiency is a rare, inherited, autosomal recessive coagulation disorder. Most mutations of this condition are found in the A-subunit with almost half these being missense mutations. Globally, approximately one in three million people suffer from this deficiency. Factor XIII deficiency is associated with severe life threatening bleeding, intracranial hemorrhage, impaired wound healing, and recurrent pregnancy losses. FXIII is known to have a potential role in mediating inflammatory processes, insulin resistance, bone metabolism, neoplasia, and angiogenesis. The algorithm provided for FXIII diagnosis and classification will enable prompt identification and early intervention for controlling potential life threatening complications. Prophylactic replacement therapy using blood products containing FXIII such as fresh frozen plasma, cryoprecipitate, or using FXIII concentrate remains the mainstay for the management of FXIII deficiency. In most parts of the world, cryoprecipitate and plasma transfusions are the only treatments available. Management developments have revealed the effectiveness and safety of recombinant FXIII concentrate for prophylaxis and treatment. The aim of this review is to provide an overview of advancements made in the management of FXIII deficiency from the time it was first detected, highlighting novel developments made in recent years. Greater research is warranted in identifying novel approaches to manage FXIII deficiency in light of its underlying pathophysiology.
Keywords: Factor XIII, Factor XIII deficiency, treatment, diagnosis, inherited coagulative disorders
Corrigendum for this paper has been published
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.